Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus PROMETHAZINE HYDROCHLORIDE.
ACTAHIST vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
1.34 mg (one capsule) orally twice daily.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic